08:56 AM EDT, 07/08/2024 (MT Newswires) -- Microbot Medical ( MBOT ) said Monday that it has completed the first procedure in a patient using its Liberty Endovascular Robotic Surgical System as part of a human clinical trial.

The trial is part of the Investigational Device Exemption for Liberty. The company expects the trial's results to support a submission to the US FDA and commercialization of the system.

"Enrolling the first patient in our pivotal human clinical trial is a significant milestone for the company, and an important step on our journey to bring Liberty to US physicians," Chief Medical Officer Juan Diaz-Cartelle said in a release.

Shares of Microbot Medical ( MBOT ) were up more than 3% in recent premarket activity.

Price: 1.0803, Change: +0.02, Percent Change: +1.44